# Gaurav Aggarwal

> Gaurav Aggarwal is a seed investor at Vivo Capital backing Health Care and Biotechnology. See 6 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Vivo Capital](https://shizune.co/investors/profile/vivo-capital)
- Location: Menlo Park, United States
- Total investments: 6
- Last investment: Jan 2026
- Lead investor: 67%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/gaurav-aggarwal-3416b682

Gaurav Aggarwal is a seed investor at Vivo Capital in Menlo Park focused on Health Care and Biotechnology. Gaurav Aggarwal is the Managing Director of Vivo Capital. He received his M.D. from Columbia University, College of Physicians and Surgeons, and his B.S. in Agricultural Economics from Cornell University.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 5 | 83% |
| Biotechnology | 5 | 83% |
| Medical | 3 | 50% |
| Pharmaceutical | 3 | 50% |
| Therapeutics | 2 | 33% |

8 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 1 | 17% |
| Series B | 1 | 17% |
| Series C | 1 | 17% |
| Series D | 1 | 17% |
| Private Equity | 1 | 17% |

6 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 5 | 83% |
| China | 1 | 17% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| EpiBiologics | EpiBiologics develops first-in-class antibody based targeted therapies against membrane and extracellular proteins that drive underlying disease biology. | $107M | Series B | Jan 08, 2026 |  |
| Serán Bioscience | Serán is a contract development and manufacturing organization providing a comprehensive suite of development, analytical and clinical manufacturing services to pharmaceutical and biotechnology companies. | $200M | Private Equity | Sep 17, 2024 |  |
| Unicycive Therapeutics | Unicycive Therapeutics provides development programs that focus on treating kidney diseases with significant unmet medical needs. It aims to open the way for a broad range of disease-modifying therapies by modifying the intracellular and extracellular concentrations of these various electrolytes and ions in Chronic Kidney Disease and Gitelman’sSyndrome and by addressing the underlying mitochondrial pathology and inflammation associated with Acute Kidney Disease.Unicycive Therapeutics was founded in 2016 and is headquartered in Los Altos, California. | $30M | Post-IPO Equity | Mar 06, 2023 |  |
| Visirna Therapeutics | Visirna Therapeutics to develop and commercialize RNAi therapeutics targeting cardiovascular and metabolic diseases. | $60M | Seed | Apr 25, 2022 |  |
| Auspex Pharmaceuticals | Auspex Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel medicines for the treatment of orphan diseases. The company's pipeline includes product candidates to address unmet medical needs in hyperkinetic movement disorders, such as chorea associated with Huntington’s disease, tardivedyskinesia, and Tourette syndrome, as well as other orphan indications. | $25M | Series D | Nov 08, 2012 |  |
| NextWave Pharmaceuticals | NextWave Pharmaceuticals, a Cupertino, CA-based pharmaceutical company that develops and commercializes products utilizing proprietary drug delivery technology. | $45M | Series C | Jan 11, 2011 |  |

6 of 6 investments shown.

## Co-investors
- [Google Ventures](https://shizune.co/investors/profile/google-ventures) — VC Fund, 2 deals together
- [Aisling Capital](https://shizune.co/investors/profile/aisling-capital) — VC Fund, 1 deal together
- [Aulis Capital](https://shizune.co/investors/profile/aulis-capital) — VC Fund, 1 deal together
- [Avego Bioscience Capital](https://shizune.co/investors/profile/avego-bioscience-capital) — VC Fund, 1 deal together
- [Bain Capital Life Sciences](https://shizune.co/investors/profile/bain-capital-life-sciences) — VC Fund, 1 deal together
- [Bay City Capital](https://shizune.co/investors/profile/bay-city-capital) — VC Fund, 1 deal together

## About Vivo Capital

VC Fund · Palo Alto, United States

The firm is a 25-year-old global investment firm focused on healthcare with approximately $5.8 billion in AUM, which we have invested in over 290 public and private companies worldwide. Headquartered in Palo Alto, California, with offices in Asia. Our team consists of 50 multi-disciplinary professionals, including, physicians, scientists,entrepreneurs, operating executives, and industry experts. The firm operates as a multi-fund investment platform, covering growth equity, private equity including buyout, venture capital, and public equity. Vivo invests broadly in healthcare across all fund strategies, including biotechnology, pharmaceuticals, medical devices, and healthcare services, with a focus on the largest healthcare markets.

5 contacts available at Vivo Capital.

| Name | Title | Profile |
| --- | --- | --- |
| Gaurav Aggarwal | Managing Director | https://shizune.co/investors/profile/gaurav-aggarwal |
| Mahendra G. Shah | Managing Director | https://shizune.co/investors/profile/mahendra-g-shah |
| Michael Chang | Managing Partner | https://shizune.co/investors/profile/michael-chang-2 |
| Shan Fu | Managing Partner, Co-CEO, and CEO of Asia Pacific | https://shizune.co/investors/profile/shan-fu |
| Chloe Zhang | Principal | https://shizune.co/investors/profile/chloe-zhang-1 |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

## FAQ

### What does Gaurav Aggarwal invest in?

Gaurav Aggarwal invests primarily in Health Care, Biotechnology and Medical startups, most often at Seed and Series B stage. Most of the 6 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Gaurav Aggarwal last invest?

The most recent investment recorded for Gaurav Aggarwal closed in Jan 2026. Shizune tracks 6 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co